Latest On SELLAS Life Sciences Group, Inc (SLS):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-12 00:38 EST | News | SELLAS Life Sciences GAAP EPS of -$0.47 misses by $0.18 | N/A |  |
| 2023-03-16 23:15 EST | News | SELLAS Life Sciences GAAP EPS of -$2.13 misses by $0.03, revenue of $1M in-line | N/A | |
| 2023-02-24 22:17 EST | News | Sellas Life Sciences dips after pricing $20M securities offering | N/A | |
| 2023-02-23 19:33 EST | News | SELLAS stock slides -32% after launching stock and warrants offering | N/A | |
| 2022-11-14 15:03 EST | News | SELLAS Life Sciences GAAP EPS of -$0.34 beats by $0.05 | N/A | |
| 2022-11-14 15:03 EST | News | SELLAS falls 39% after delaying key milestone for cancer drug | N/A | |
| 2022-11-10 23:10 EST | News | Sellas rises as GPS/Keytruda combo shows survival, disease control benefit in ovarian cancer trial | N/A | |
| 2022-08-12 07:49 EST | News | SELLAS Life Sciences GAAP EPS of -$0.41 misses by $0.02 | N/A | |
| 2022-08-10 05:35 EST | News | SELLAS Life Sciences rises 9% after cancer drug shows promising result in animal study | N/A | |
| 2022-06-27 15:37 EST | News | Sellas posts positive data from phase 1 trial of lymphoma, acute myeloid leukemia therapy | N/A | |
| 2022-06-17 01:19 EST | News | SELLAS Life Sciences Group (SLS) Investor Presentation - Slideshow | N/A | |
| 2022-06-09 00:39 EST | News | Sellas' GPS, Opdivo combo shows promise in early stage study in type of lung cancer | N/A | |
| 2022-05-26 17:45 EST | News | Sellas announces topline data for lead asset in Ovarian cancer | N/A | |
| 2022-05-13 00:44 EST | News | SELLAS Life Sciences GAAP EPS of -$1.05, revenue of $1M | N/A | |
| 2022-04-06 21:12 EST | News | Sellas Life Sciences gets China regulator nod to start trial of immunotherapy 3D189 | N/A | |
| 2022-04-01 12:06 EST | News | SELLAS Life Sciences plunged 24% on $25M stock offering | N/A | |
| 2022-03-31 17:59 EST | News | Sellas Life Sciences stock slumps on securities offering | N/A | |
| 2022-03-31 17:59 EST | News | Sellas Life Sciences licenses CDK9 inhibitor from China's GenFleet Therapeutics | N/A | |
| 2022-02-02 08:19 EST | News | Sellas, Merck complete enrollment in GPS-Keytruda combo phase 1/2 trial in ovarian cancer | N/A | |
| 2022-01-27 20:28 EST | News | SELLAS Life Sciences' IND application for galinpepimut-S accepted in China | N/A | |
| 2021-11-24 05:30 EST | News | Sellas Life announces final court approval of settlement of derivative litigation | N/A | |
| 2021-11-24 05:30 EST | News | Warning: SLS is at high risk of performing badly | N/A | |
| 2021-11-13 03:57 EST | News | SELLAS Life Sciences EPS misses by $0.09 | N/A | |
| 2021-08-13 00:18 EST | News | SELLAS Life Sciences EPS beats by $0.11 | N/A | |
| 2021-07-22 01:01 EST | News | Sellas Life Sciences nabs new U.S. patent for galinpepimut-s combo in WT1-expressing cancers | N/A | |
| 2021-07-22 00:57 EST | News | SELLAS Life Sciences updates on at-the-market offering | N/A | |
| 2021-07-22 00:31 EST | News | SELLAS Life Sciences shares rise on data from early-stage galinpepimut-S study | N/A | |
| 2021-07-22 00:23 EST | News | SELLAS ovarian cancer candidate shows promise in early-stage trial | N/A | |
| 2021-07-21 23:56 EST | News | SELLAS rated new overweight at Cantor noting the potential of blood cancer therapy | N/A | |
| 2021-03-24 06:05 EST | News | SELLAS Life Sciences EPS misses by $0.28 | N/A | |
| 2021-02-23 02:51 EST | News | Sellas: Late-Stage Biotech Approaches 2023 Approval With Solid Funding | N/A | |
| 2021-02-04 01:42 EST | News | SELLAS Life Sciences jumps 43% after Reddit mentions | N/A | |
| 2020-12-23 04:40 EST | Analyst Rating | The Analyst Target Price has increased from $8 to $10. | Buy | |
| 2020-12-21 14:55 EST | News | Sellas' galinpepimut-S combo shows promising action in early-stage solid tumor studies | N/A | |
| 2020-12-17 23:52 EST | News | Sellas Life Sciences strengthens balance sheet with addition of $30.5M | N/A | |
| 2020-12-14 07:39 EST | News | Sellas Life Sciences prices $16.2M direct offering | N/A | |
| 2020-12-11 11:44 EST | News | Nelipepimut-S data from breast cancer study fails to lift SELLAS Life Sciences | N/A | |
| 2020-12-08 12:06 EST | News | SELLAS and 3D Medicines in exclusive license agreement for development and commercialization of GPS and GPS+ in Greater China | N/A | |
| 2020-11-26 21:35 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-17 21:13 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-17 05:25 EST | Earnings Estimate | An EPS average of -$0.35 is estimated for the quarter ending on March 31, 2021. | Buy | |
| 2020-11-14 11:21 EST | News | SELLAS Life Sciences EPS misses by $0.26 | N/A | |
| 2020-11-08 00:54 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 17:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 14:03 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 06:16 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-10 05:25 EST | News | SELLAS Life gets green signal to initiate late-stage blood cancer study with GPS in France | N/A | |
| 2020-09-01 21:38 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-20 13:43 EST | Analyst Rating | The Analyst Target Price has decreased from $8.5 to $8. | Neutral | |
| 2020-08-17 01:43 EST | Financials | Company financials have been released. | Neutral | |
About SELLAS Life Sciences Group, Inc (SLS):
SELLAS Life Sciences Group, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and is in various development phases as a potential treatment for ovarian cancer. It also develops nelipepimut-S that is in Phase 2b clinical trials for the treatment of breast cancer. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. SELLAS Life Sciences Group, Inc. was founded in 2012 and is headquartered in New York, New York.
General
- Name SELLAS Life Sciences Group, Inc
- Symbol SLS
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 5
- Last Split Factor1:50
- Last Split Date2019-11-08
- Fiscal Year EndDecember
- IPO Date2017-12-29
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Web URLhttp://www.sellaslifesciences.com
View More
Valuation
- Trailing PE 0.62
- Price/Book (Most Recent Quarter) 17.57
View More
Financials
- Most Recent Quarter 2020-09-30
- Next Quarter EPS Estimate -$0.30
- Return on Assets -55%
- Return on Equity -220%
- Earnings Per Share -$1.35
- Revenue Per Share $0
- Quarterly Earnings Growth 0%
View More
Highlights
- Market Capitalization 149.61 million
- PE Ratio -2.1
- Analyst Target Price $10
- Book Value Per Share $0.84
View More
Share Statistics
- Shares Outstanding 14.19 million
- Shares Float 9.22 million
- % Held by Insiders 198%
- % Held by Institutions 14.24%
- Shares Short 805001
- Shares Short Prior Month 960419
- Short Ratio 0.22
- Short % of Float 6%
- Short % of Shares Outstanding 6%
View More
Technicals
- Beta 1.87
- 52 Week High $12.18
- 52 Week Low $1.46
- 50 Day Moving Average 8.9
- 200 Day Moving Average 5.21
View More
Dividends
- Dividend Date 2019-11-08
- ExDividend Date N/A
- Dividend Yield 0%
View More
SELLAS Life Sciences Group, Inc (SLS) Dividend Calendar:
SLS's last dividend payment was made to shareholders on November 8, 2019.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
SELLAS Life Sciences Group, Inc (SLS) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-11-13 | $N/A | -$0.53 | -$0.27 | -96.3% |
| 2020-06-30 | 2020-08-13 | $N/A | -$0.66 | -$0.64 | -3.13% |
| 2020-03-31 | 2020-05-14 | $N/A | -$0.66 | ||
| 2019-12-31 | 2020-03-13 | $N/A | -$1.54 | -$0.72 | -113.89% |
| 2019-09-30 | 2019-11-14 | $N/A | -$2.68 | -$1.00 | -168% |
| 2019-06-30 | 2019-08-14 | $N/A | -$6.50 | -$9.00 | 27.78% |
| 2019-03-31 | 2019-05-15 | $N/A | -$11.00 | -$11.50 | 4.35% |
| 2018-12-31 | 2019-03-22 | $N/A | -$20.00 | -$11.75 | -70.21% |
| 2018-09-30 | 2018-11-14 | $N/A | -$26.50 | -$20.25 | -30.86% |
| 2018-06-30 | 2018-08-14 | $N/A | -$63.00 | -$51.50 | -22.33% |
| 2018-03-31 | 2018-05-15 | $N/A | -$83.50 | -$46.50 | -79.57% |
| 2017-09-30 | 2017-11-09 | $N/A | -$135.00 | -$4.50 | -2900% |
| 2017-06-30 | 2017-08-14 | $N/A | -$6.60 | -$5.40 | -22.22% |
| 2017-03-31 | 2017-05-10 | $N/A | -$13.50 | -$6.60 | -104.55% |
| 2016-12-31 | 2017-03-15 | $N/A | -$14.70 | -$15.60 | 5.77% |
| 2016-09-30 | 2016-11-09 | $N/A | -$18.00 | -$27.00 | 33.33% |
| 2016-06-30 | 2016-08-09 | $N/A | $18.00 | -$37.50 | 148% |
| 2016-03-31 | 2016-05-10 | $N/A | -$54.00 | -$38.40 | -40.63% |
| 2015-12-31 | 2016-03-10 | $6.13 million | -$72.00 | -$32.00 | -125% |
| 2015-09-30 | 2015-11-09 | $-9514000 | -$2.20 | -$1.37 | -60.58% |
| 2015-06-30 | 2015-08-06 | $3.38 million | -$2.00 | -$1.84 | -8.7% |
| 2015-03-31 | 2015-05-07 | $2.75 million | -$1.60 | -$1.73 | 7.51% |
| 2014-12-31 | 2015-03-05 | $9.48 million | -$1.20 | -$2.10 | 42.86% |
| 2014-09-30 | 2014-11-03 | $-2884000 | -$0.05 | -$0.11 | 54.55% |
| 2014-06-30 | 2014-08-11 | $4.5 million | -$5,100.00 | -$2,700.00 | -88.89% |
| 2014-03-31 | 2014-05-06 | $-165000 | -$600.00 | -$2,062.50 | 70.91% |
| 2013-12-31 | 2014-03-17 | $1.32 million | -$13,800.00 | -$2,766.67 | -398.79% |
| 2013-09-30 | 2013-11-06 | $1.17 million | -$3,300.00 | -$3,300.00 | 0% |
| 2013-06-30 | 2013-08-08 | $N/A | -$3,300.00 | -$3,112.50 | -6.02% |
| 2013-03-31 | 2013-05-09 | $N/A | -$3,300.00 | -$2,228.57 | -48.08% |
| 2012-12-31 | 2013-03-12 | $N/A | -$1,200.00 | -$3,042.86 | 60.56% |
| 2012-09-30 | 2012-11-13 | $N/A | -$2,700.00 | -$2,550.00 | -5.88% |
| 2012-06-30 | 2012-08-14 | $N/A | -$210.00 | -$4,800.00 | 95.63% |
| 2012-03-31 | 2012-05-14 | $N/A | -$15,600.00 | -$3,000.00 | -420% |
| 2011-12-31 | 2012-03-28 | $1,200.00 | -$4,500.00 | 126.67% | |
| 2011-09-30 | 2011-11-14 | $N/A | -$3,900.00 | -$4,800.00 | 18.75% |
| 2011-06-30 | 2011-08-15 | $N/A | -$1,200.00 | -$2,100.00 | 42.86% |
| 2011-03-31 | 2011-05-15 | -$5,672.40 | |||
| 2010-09-30 | 2010-11-15 | -$6,900.00 | -$7,050.00 | 2.13% | |
| 2010-06-30 | 2010-08-11 | -$3,600.00 | -$7,200.00 | 50% | |
| 2010-03-31 | 2010-05-17 | -$7,200.00 | -$8,100.00 | 11.11% | |
| 2009-12-31 | 2010-03-31 | -$11,400.00 | -$7,500.00 | -52% | |
| 2009-09-30 | 2009-11-16 | -$5,846.95 | |||
| 2009-06-30 | 2009-08-14 | -$11,100.00 | -$9,000.00 | -23.33% | |
| 2009-03-31 | 2009-05-15 | -$9,000.00 | -$8,700.00 | -3.45% | |
| 2008-12-31 | 2009-03-18 | -$8,700.00 | $2,400.00 | -462.5% | |
| 2008-09-30 | 2008-11-14 | -$7,500.00 | -$9,600.00 | 21.88% | |
| 2008-06-30 | 2008-08-14 | -$10,200.00 | -$6,600.00 | -54.55% | |
| 2008-03-31 | 2008-04-15 | -$11,700.00 | -$6,000.00 | -95% |
SELLAS Life Sciences Group, Inc (SLS) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
SELLAS Life Sciences Group, Inc (SLS) Chart:
SELLAS Life Sciences Group, Inc (SLS) News:
Below you will find a list of latest news for SELLAS Life Sciences Group, Inc (SLS) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
SELLAS Life Sciences Group, Inc (SLS) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2024-05-17 | 0.5 | 1.35 | CALL | 0 | 19 | 422.1 | TRUE | 0 | 0 |
| 2024-05-17 | 1 | 0.6 | CALL | 24 | 342 | 193.95 | TRUE | -0.1 | -0.14 |
| 2024-05-17 | 1.5 | 0.3 | CALL | 66 | 5973 | 136.42 | TRUE | 0 | 0 |
| 2024-05-17 | 2 | 0.14 | CALL | 101 | 7885 | 185.46 | FALSE | -0.02 | -0.13 |
| 2024-05-17 | 3 | 0.1 | CALL | 135 | 4202 | 257.95 | FALSE | 0 | 0 |
| 2024-05-17 | 4 | 0.09 | CALL | 1 | 202 | 309.19 | FALSE | 0.09 | 0 |
| 2024-05-17 | 5 | 0.1 | CALL | 0 | 117 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 0.5 | 0.01 | PUT | 0 | 12 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 1 | 0.07 | PUT | 112 | 1112 | 210.34 | FALSE | -0.03 | -0.3 |
| 2024-05-17 | 1.5 | 0.28 | PUT | 18 | 322 | 205.02 | FALSE | 0.28 | 0 |
| 2024-05-17 | 2 | 0.55 | PUT | 2 | 231 | 153.17 | TRUE | 0.55 | 0 |
| 2024-05-17 | 3 | 1.6 | PUT | 2 | 1 | 296.54 | TRUE | 1.6 | 0 |
| 2024-05-17 | 4 | 0 | PUT | 0 | 0 | 381.12 | TRUE | 0 | 0 |
| 2024-05-17 | 5 | 0 | PUT | 0 | 0 | 484.54 | TRUE | 0 | 0 |
| 2024-06-21 | 0.5 | 1 | CALL | 0 | 0 | 604.74 | TRUE | 0 | 0 |
| 2024-06-21 | 1 | 0.6 | CALL | 11 | 27 | 117.21 | TRUE | 0 | 0 |
| 2024-06-21 | 1.5 | 0.3 | CALL | 212 | 465 | 115.32 | TRUE | -0.1 | -0.25 |
| 2024-06-21 | 2 | 0.2 | CALL | 2 | 4097 | 139.77 | FALSE | -0.05 | -0.2 |
| 2024-06-21 | 3 | 0.15 | CALL | 0 | 259 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 4 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 0.5 | 0.05 | PUT | 0 | 105 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 1 | 0.15 | PUT | 0 | 15 | 170.53 | FALSE | 0 | 0 |
| 2024-06-21 | 1.5 | 0.33 | PUT | 0 | 10 | 170.72 | FALSE | 0 | 0 |
| 2024-06-21 | 2 | 0 | PUT | 0 | 0 | 193.39 | TRUE | 0 | 0 |
| 2024-06-21 | 3 | 0 | PUT | 0 | 0 | 244.19 | TRUE | 0 | 0 |
| 2024-06-21 | 4 | 0 | PUT | 0 | 0 | 276.96 | TRUE | 0 | 0 |
| 2024-06-21 | 5 | 0 | PUT | 0 | 0 | 233.99 | TRUE | 0 | 0 |
| 2024-07-19 | 0.5 | 0.75 | CALL | 0 | 100 | 374.45 | TRUE | 0 | 0 |
| 2024-07-19 | 1 | 0.55 | CALL | 700 | 12167 | 152.87 | TRUE | -0.15 | -0.21 |
| 2024-07-19 | 1.5 | 0.4 | CALL | 202 | 8654 | 129.23 | TRUE | 0 | 0 |
| 2024-07-19 | 2 | 0.25 | CALL | 27 | 14248 | 130.8 | FALSE | -0.05 | -0.17 |
| 2024-07-19 | 3 | 0.16 | CALL | 7 | 302 | 154.57 | FALSE | -0.01 | -0.06 |
| 2024-07-19 | 4 | 0.15 | CALL | 50 | 1181 | 183.03 | FALSE | 0 | 0 |
| 2024-07-19 | 5 | 0.1 | CALL | 0 | 205 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 6 | 0.1 | CALL | 0 | 370 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 0.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 1 | 0.15 | PUT | 0 | 6 | 154.02 | FALSE | 0 | 0 |
| 2024-07-19 | 1.5 | 0 | PUT | 0 | 0 | 159.34 | FALSE | 0 | 0 |
| 2024-07-19 | 2 | 0.9 | PUT | 0 | 356 | 177.01 | TRUE | 0 | 0 |
| 2024-07-19 | 3 | 0 | PUT | 0 | 0 | 202.63 | TRUE | 0 | 0 |
| 2024-07-19 | 4 | 0 | PUT | 0 | 0 | 202.68 | TRUE | 0 | 0 |
| 2024-07-19 | 5 | 0 | PUT | 0 | 0 | 238.25 | TRUE | 0 | 0 |
| 2024-07-19 | 6 | 0 | PUT | 0 | 0 | 188.66 | TRUE | 0 | 0 |
| 2024-08-16 | 0.5 | 0 | CALL | 0 | 0 | 428.37 | TRUE | 0 | 0 |
| 2024-08-16 | 1 | 0.5 | CALL | 0 | 10 | 93.98 | TRUE | 0 | 0 |
| 2024-08-16 | 1.5 | 0.45 | CALL | 0 | 10 | 143.23 | TRUE | 0 | 0 |
| 2024-08-16 | 2 | 0.25 | CALL | 0 | 2384 | 142.18 | FALSE | 0 | 0 |
| 2024-08-16 | 3 | 0.2 | CALL | 0 | 13 | 130.29 | FALSE | 0 | 0 |
| 2024-08-16 | 4 | 0.15 | CALL | 0 | 310 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 5 | 0.1 | CALL | 100 | 100 | 158.59 | FALSE | 0.1 | 0 |
| 2024-08-16 | 0.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 1 | 0.25 | PUT | 0 | 1 | 238.55 | FALSE | 0 | 0 |
| 2024-08-16 | 1.5 | 0 | PUT | 0 | 0 | 197.53 | FALSE | 0 | 0 |
| 2024-08-16 | 2 | 0.8 | PUT | 0 | 62 | 162.31 | TRUE | 0 | 0 |
| 2024-08-16 | 3 | 0 | PUT | 0 | 0 | 177.84 | TRUE | 0 | 0 |
| 2024-08-16 | 4 | 0 | PUT | 0 | 0 | 170.15 | TRUE | 0 | 0 |
| 2024-08-16 | 5 | 0 | PUT | 0 | 0 | 193.12 | TRUE | 0 | 0 |
| 2024-09-20 | 0.5 | 1.1 | CALL | 0 | 9 | 504.4 | TRUE | 0 | 0 |
| 2024-09-20 | 1 | 0.75 | CALL | 0 | 29 | 0 | TRUE | 0 | 0 |
| 2024-09-20 | 1.5 | 0.5 | CALL | 0 | 1518 | 82.74 | TRUE | 0 | 0 |
| 2024-09-20 | 2 | 0.33 | CALL | 9 | 2228 | 118.48 | FALSE | 0.03 | 0.1 |
| 2024-09-20 | 3 | 0.2 | CALL | 0 | 1 | 199.06 | FALSE | 0 | 0 |
| 2024-09-20 | 4 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-09-20 | 5 | 0.15 | CALL | 0 | 15 | 0 | FALSE | 0 | 0 |
| 2024-09-20 | 0.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-09-20 | 1 | 0 | PUT | 0 | 0 | 158.38 | FALSE | 0 | 0 |
| 2024-09-20 | 1.5 | 0.56 | PUT | 0 | 1 | 144.2 | FALSE | 0 | 0 |
| 2024-09-20 | 2 | 1 | PUT | 0 | 1 | 156.48 | TRUE | 0 | 0 |
| 2024-09-20 | 3 | 0 | PUT | 0 | 0 | 100.13 | TRUE | 0 | 0 |
| 2024-09-20 | 4 | 0 | PUT | 0 | 0 | 166.3 | TRUE | 0 | 0 |
| 2024-09-20 | 5 | 0 | PUT | 0 | 0 | 187.32 | TRUE | 0 | 0 |
| 2024-10-18 | 0.5 | 0.85 | CALL | 0 | 907 | 342.2 | TRUE | 0 | 0 |
| 2024-10-18 | 1 | 0.7 | CALL | 50 | 1359 | 103.24 | TRUE | -0.1 | -0.13 |
| 2024-10-18 | 1.5 | 0.4 | CALL | 121 | 18629 | 87.79 | TRUE | -0.18 | -0.31 |
| 2024-10-18 | 2 | 0.34 | CALL | 56 | 15660 | 110.53 | FALSE | -0.06 | -0.15 |
| 2024-10-18 | 3 | 0.24 | CALL | 12 | 145 | 126.57 | FALSE | 0.02 | 0.09 |
| 2024-10-18 | 4 | 0.14 | CALL | 0 | 205 | 0 | FALSE | 0 | 0 |
| 2024-10-18 | 5 | 0.15 | CALL | 216 | 100 | 142.22 | FALSE | 0.05 | 0.5 |
| 2024-10-18 | 0.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-10-18 | 1 | 0 | PUT | 0 | 10 | 155.16 | FALSE | 0 | 0 |
| 2024-10-18 | 1.5 | 0 | PUT | 0 | 0 | 160.42 | FALSE | 0 | 0 |
| 2024-10-18 | 2 | 1 | PUT | 0 | 4 | 156.87 | TRUE | 0 | 0 |
| 2024-10-18 | 3 | 2 | PUT | 0 | 10 | 211.87 | TRUE | 0 | 0 |
| 2024-10-18 | 4 | 0 | PUT | 0 | 0 | 154.71 | TRUE | 0 | 0 |
| 2024-10-18 | 5 | 0 | PUT | 0 | 0 | 160.78 | TRUE | 0 | 0 |
Latest SLS Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:06 PM EST | 5 | $2.29 |
| Jun 13, 2022 7:12 PM EST | 100 | $2.265 |
| Jun 13, 2022 7:30 PM EST | 100 | $2.265 |
| Jun 13, 2022 7:39 PM EST | 2 | $2.28 |
| Jun 13, 2022 7:40 PM EST | 100 | $2.27 |
SELLAS Life Sciences Group, Inc (SLS) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-11 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1390478/999999999520001404/9999999995-20-001404-index.htm |
| 2018-07-26 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1390478/000000000018022947/0000000000-18-022947-index.htm |
| 2019-05-29 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1390478/000000000019009082/0000000000-19-009082-index.htm |
| 2019-10-01 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1390478/000000000019014150/0000000000-19-014150-index.htm |
| 2020-06-05 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1390478/000000000020005052/0000000000-20-005052-index.htm |
| 2020-08-21 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1390478/000000000020007844/0000000000-20-007844-index.htm |
| 2018-09-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1390478/000089924318025346/0000899243-18-025346-index.htm |
| 2019-03-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1390478/000089924319008194/0000899243-19-008194-index.htm |
| 2019-03-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1390478/000089924319008198/0000899243-19-008198-index.htm |
| 2019-03-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1390478/000089924319008199/0000899243-19-008199-index.htm |
| 2019-03-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1390478/000089924319008201/0000899243-19-008201-index.htm |
| 2019-03-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1390478/000089924319008202/0000899243-19-008202-index.htm |
| 2019-03-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1390478/000089924319008204/0000899243-19-008204-index.htm |
| 2019-03-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1390478/000089924319008205/0000899243-19-008205-index.htm |
| 2019-03-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1390478/000089924319008206/0000899243-19-008206-index.htm |
| 2019-03-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1390478/000089924319008207/0000899243-19-008207-index.htm |
| 2018-07-18 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1390478/000090266418002884/0000902664-18-002884-index.htm |
| 2019-01-17 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1390478/000090266419000274/0000902664-19-000274-index.htm |
| 2018-07-23 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1390478/000101359418000463/0001013594-18-000463-index.htm |
| 2020-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1390478/000101359420000125/0001013594-20-000125-index.htm |
| 2019-02-12 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1390478/000103738919000077/0001037389-19-000077-index.htm |
| 2020-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1390478/000103738920000128/0001037389-20-000128-index.htm |
| 2019-10-30 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1390478/000110465919057371/0001104659-19-057371-index.htm |
| 2019-10-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1390478/000110465919057956/0001104659-19-057956-index.htm |
| 2019-11-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1390478/000110465919060564/0001104659-19-060564-index.htm |
| 2020-01-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1390478/000110465920002021/0001104659-20-002021-index.htm |
| 2020-01-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1390478/000110465920002807/0001104659-20-002807-index.htm |
| 2020-01-10 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1390478/000110465920002811/0001104659-20-002811-index.htm |
| 2020-01-17 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1390478/000110465920004932/0001104659-20-004932-index.htm |
| 2020-03-13 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1390478/000110465920033156/0001104659-20-033156-index.htm |
| 2020-03-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1390478/000110465920034284/0001104659-20-034284-index.htm |
| 2020-03-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1390478/000110465920034285/0001104659-20-034285-index.htm |
| 2020-03-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1390478/000110465920034286/0001104659-20-034286-index.htm |
| 2020-03-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1390478/000110465920034288/0001104659-20-034288-index.htm |
| 2020-03-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1390478/000110465920034289/0001104659-20-034289-index.htm |
| 2020-03-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1390478/000110465920034290/0001104659-20-034290-index.htm |
| 2020-03-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1390478/000110465920034291/0001104659-20-034291-index.htm |
| 2020-04-23 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1390478/000110465920049860/0001104659-20-049860-index.htm |
| 2020-04-24 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1390478/000110465920050563/0001104659-20-050563-index.htm |
| 2020-05-29 | S-1 | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1390478/000110465920067795/0001104659-20-067795-index.htm |
| 2020-06-03 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1390478/000110465920069457/0001104659-20-069457-index.htm |
| 2020-06-09 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1390478/000110465920071368/0001104659-20-071368-index.htm |
| 2020-06-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1390478/000110465920072436/0001104659-20-072436-index.htm |
| 2020-06-11 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1390478/000110465920072467/0001104659-20-072467-index.htm |
| 2020-08-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1390478/000110465920089747/0001104659-20-089747-index.htm |
| 2020-08-14 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1390478/000110465920095588/0001104659-20-095588-index.htm |
| 2020-08-21 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1390478/000110465920097531/0001104659-20-097531-index.htm |
| 2019-04-05 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1390478/000114420419018433/0001144204-19-018433-index.htm |
| 2019-05-23 | S-1 | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1390478/000114420419028003/0001144204-19-028003-index.htm |
| 2019-05-24 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1390478/000114420419028175/0001144204-19-028175-index.htm |
| 2019-05-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1390478/000114420419029019/0001144204-19-029019-index.htm |
| 2019-05-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1390478/000114420419029269/0001144204-19-029269-index.htm |
| 2019-06-06 | S-1/A | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1390478/000114420419030128/0001144204-19-030128-index.htm |
| 2019-06-13 | S-1/A | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1390478/000114420419030762/0001144204-19-030762-index.htm |
| 2019-06-13 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1390478/000114420419030766/0001144204-19-030766-index.htm |
| 2019-06-13 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1390478/000114420419030768/0001144204-19-030768-index.htm |
| 2019-06-18 | 424B4 | Prospectus [Rule 424(b)(4)] | https://www.sec.gov/Archives/edgar/data/1390478/000114420419031239/0001144204-19-031239-index.htm |
| 2019-06-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1390478/000114420419031351/0001144204-19-031351-index.htm |
| 2019-07-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1390478/000114420419033573/0001144204-19-033573-index.htm |
| 2019-07-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1390478/000114420419034049/0001144204-19-034049-index.htm |
| 2019-07-26 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/1390478/000114420419036263/0001144204-19-036263-index.htm |
| 2019-08-05 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1390478/000114420419037528/0001144204-19-037528-index.htm |
| 2019-09-20 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1390478/000114420419045463/0001144204-19-045463-index.htm |
| 2019-10-04 | S-3/A | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1390478/000114420419047400/0001144204-19-047400-index.htm |
| 2019-10-04 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1390478/000114420419047401/0001144204-19-047401-index.htm |
| 2018-07-13 | 424B4 | Prospectus [Rule 424(b)(4)] | https://www.sec.gov/Archives/edgar/data/1390478/000119312518217974/0001193125-18-217974-index.htm |
| 2018-07-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1390478/000119312518220669/0001193125-18-220669-index.htm |
| 2018-07-19 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1390478/000119312518221592/0001193125-18-221592-index.htm |
| 2018-07-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1390478/000119312518223727/0001193125-18-223727-index.htm |
| 2018-07-23 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1390478/000119312518223824/0001193125-18-223824-index.htm |
| 2018-07-25 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1390478/000119312518225863/0001193125-18-225863-index.htm |
| 2018-07-26 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1390478/000119312518227864/0001193125-18-227864-index.htm |
| 2018-07-26 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1390478/000119312518227881/0001193125-18-227881-index.htm |
| 2018-08-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1390478/000119312518239831/0001193125-18-239831-index.htm |
| 2018-10-10 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1390478/000119312518296150/0001193125-18-296150-index.htm |
| 2018-10-17 | 8-K/A | Current report | https://www.sec.gov/Archives/edgar/data/1390478/000119312518301115/0001193125-18-301115-index.htm |
| 2019-01-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1390478/000119312519003893/0001193125-19-003893-index.htm |
| 2019-06-24 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1390478/000119312519180113/0001193125-19-180113-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1390478/000119312520038502/0001193125-20-038502-index.htm |
| 2018-12-19 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1390478/000120919118063530/0001209191-18-063530-index.htm |
| 2019-01-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1390478/000120919119001612/0001209191-19-001612-index.htm |
| 2019-10-09 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1390478/000130049119000007/0001300491-19-000007-index.htm |
| 2018-07-23 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1390478/000138713118003284/0001387131-18-003284-index.htm |
| 2019-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1390478/000138713119001111/0001387131-19-001111-index.htm |
| 2019-06-24 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1390478/000138713119004559/0001387131-19-004559-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1390478/000138713120001689/0001387131-20-001689-index.htm |
| 2020-08-25 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1390478/000138713120007841/0001387131-20-007841-index.htm |
| 2018-08-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1390478/000139047818000022/0001390478-18-000022-index.htm |
| 2018-10-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1390478/000139047818000025/0001390478-18-000025-index.htm |
| 2018-10-05 | 8-K/A | Current report | https://www.sec.gov/Archives/edgar/data/1390478/000139047818000027/0001390478-18-000027-index.htm |
| 2018-10-24 | 8-K/A | Current report | https://www.sec.gov/Archives/edgar/data/1390478/000139047818000030/0001390478-18-000030-index.htm |
| 2018-11-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1390478/000139047818000032/0001390478-18-000032-index.htm |
| 2018-11-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1390478/000139047818000035/0001390478-18-000035-index.htm |
| 2018-11-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1390478/000139047818000037/0001390478-18-000037-index.htm |
| 2018-12-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1390478/000139047818000039/0001390478-18-000039-index.htm |
| 2018-12-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1390478/000139047818000043/0001390478-18-000043-index.htm |
| 2019-02-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1390478/000139047819000007/0001390478-19-000007-index.htm |
| 2019-03-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1390478/000139047819000011/0001390478-19-000011-index.htm |
| 2019-03-22 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1390478/000139047819000017/0001390478-19-000017-index.htm |
| 2019-03-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1390478/000139047819000019/0001390478-19-000019-index.htm |
| 2019-04-30 | 10-K/A | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1390478/000139047819000023/0001390478-19-000023-index.htm |
| 2019-05-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1390478/000139047819000028/0001390478-19-000028-index.htm |
| 2019-05-15 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1390478/000139047819000030/0001390478-19-000030-index.htm |
| 2019-07-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1390478/000139047819000033/0001390478-19-000033-index.htm |
| 2019-07-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1390478/000139047819000035/0001390478-19-000035-index.htm |
| 2019-07-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1390478/000139047819000037/0001390478-19-000037-index.htm |
| 2019-08-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1390478/000139047819000044/0001390478-19-000044-index.htm |
| 2019-08-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1390478/000139047819000045/0001390478-19-000045-index.htm |
| 2019-09-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1390478/000139047819000048/0001390478-19-000048-index.htm |
| 2019-11-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1390478/000139047819000056/0001390478-19-000056-index.htm |
| 2019-11-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1390478/000139047819000057/0001390478-19-000057-index.htm |
| 2019-11-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1390478/000139047819000061/0001390478-19-000061-index.htm |
| 2020-03-13 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1390478/000139047820000007/0001390478-20-000007-index.htm |
| 2020-03-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1390478/000139047820000009/0001390478-20-000009-index.htm |
| 2020-05-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1390478/000139047820000014/0001390478-20-000014-index.htm |
| 2020-05-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1390478/000139047820000015/0001390478-20-000015-index.htm |
| 2020-08-13 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1390478/000139047820000026/0001390478-20-000026-index.htm |
| 2020-08-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1390478/000139047820000029/0001390478-20-000029-index.htm |
| 2020-08-31 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1390478/000139047820000030/0001390478-20-000030-index.htm |
| 2020-09-21 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1390478/000149315220018054/0001493152-20-018054-index.htm |
| 2019-01-03 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1390478/000153561019000006/0001535610-19-000006-index.htm |
| 2018-07-26 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1390478/999999999518001908/9999999995-18-001908-index.htm |
| 2019-06-13 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1390478/999999999519001347/9999999995-19-001347-index.htm |
| 2019-10-11 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1390478/999999999519002300/9999999995-19-002300-index.htm |
| 2020-06-11 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1390478/999999999520001404/9999999995-20-001404-index.htm |
| 2020-08-24 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1390478/999999999520002237/9999999995-20-002237-index.htm |
SELLAS Life Sciences Group, Inc (SLS) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of SELLAS Life Sciences Group, Inc (SLS). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 198%Institutional Ownership: 1424%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-03-12 | John Thomas Burns | VP, Finance & Corp Controller | Buy | 15,000.00 | 15,000.00 | https://www.sec.gov/Archives/edgar/data/1390478/000110465920034284/0001104659-20-034284-index.htm | ||
| 2020-03-12 | BARBARA A WOOD | EVP, Gen. Counsel, Corp. Sec. | Buy | 35,000.00 | 35,000.00 | https://www.sec.gov/Archives/edgar/data/1390478/000110465920034291/0001104659-20-034291-index.htm | ||
| 2018-12-31 | Angelos M. Stergiou | President and CEO | Sell | 23,277.00 | 1.25 | 29,189.36 | 426,858.00 | https://www.sec.gov/Archives/edgar/data/1390478/000120919119001612/0001209191-19-001612-index.htm |
| 2020-03-12 | Angelos M. Stergiou | President and CEO | Buy | 95,000.00 | 95,000.00 | https://www.sec.gov/Archives/edgar/data/1390478/000110465920034286/0001104659-20-034286-index.htm |